Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

Condition:   Leiomyosarcoma Intervention:   Drug: Dinutuximab Beta, Zoledronic acid, Interleukin-2 Sponsors:   Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest;   EUSA Pharma, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials